A phase I, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumours

被引：0
|
作者：
Tolcher, A. W. [1 ]
Falchook, G. [2 ]
Bendell, J. C. [3 ]
Ungar, D. [4 ]
Boni, J. [4 ]
Chao, G. [4 ]
Patel, M. R. [3 ,5 ]
机构：
[1] NEXT Oncol, Clin Res, San Antonio, TX USA
[2] HealthONE, Drug Dev Program, Sarah Cannon Res Inst, Denver, CO USA
[3] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[4] ADC Therapeut Inc, Clin Dev, Murray Hill, NJ USA
[5] Florida Canc Specialists, Sarasota Drug Dev Unit, Sarasota, FL USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
468P
引用
收藏
页码：176 / +
页数：2
相关论文
共 50 条
  • [21] Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
    Jason D. Lickliter
    Mark Voskoboynik
    Linda Mileshkin
    Hui K. Gan
    Ganessan Kichenadasse
    Kathy Zhang
    Maggie Zhang
    Zhiyu Tang
    Michael Millward
    British Journal of Cancer, 2022, 126 : 576 - 585
  • [22] A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY AND TOLERABILITY STUDY OF NC762 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
    Myint, Han
    Shah, Satish
    Gutierrez, Martin
    Zsiros, Emese
    Nelson, Megan
    Zeidan, Stephanie
    Myrthil, Nadia
    Morawski, Aaron
    Barbu, Alina
    Shaik, Jahangheer
    Zhou, Chelsea
    Kanellopoulou, Chrysi
    Copeland, Ron
    Cusumano, Zachary
    Flies, Dallas
    Langermann, Solomon
    Lorusso, Patricia
    Odunsi, Kunle
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A781 - A781
  • [23] Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study
    Hong, Ruoxi
    Xia, Wen
    Wang, Liye
    Lee, Kaping
    Lu, Qianyi
    Jiang, Kuikui
    Li, Shengfeng
    Yu, Jinquan
    Wei, Jin
    Tang, Weijia
    Zhou, Danyang
    An, Xin
    Huang, Jiajia
    Xue, Cong
    Bi, Xiwen
    Shi, Yanxia
    Yuan, Zhongyu
    Xu, Fei
    Wang, Shusen
    CANCER COMMUNICATIONS, 2021, 41 (02) : 171 - 182
  • [24] Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in- human, open-label, dose-escalation phase I study with expansion cohort
    Burris, Howard A.
    Bakewell, Suzanne
    Bendell, Johanna C.
    Infante, Jeffrey
    Jones, Suzanne F.
    Spigel, David R.
    Weiss, Glen J.
    Ramanathan, Ramesh K.
    Ogden, Angela
    Von Hoff, Daniel
    ESMO OPEN, 2016, 1 (06)
  • [25] A phase I/II, open-label, dose-escalation, and cohort-expansion study evaluating the safety, pharmacokinetics, and therapeutic activity of OBI-999 in patients with advanced solid tumors.
    Tsimberidou, Apostolia Maria
    Ajani, Jaffer A.
    Hsu, Pei
    Chen, I-Ju
    Pearce, Tillman E.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] A phase I dose escalation study to assess the safety tolerability and pharmacokinetics of ETS2101 in patients (pts) with advanced solid tumours
    Plummer, R.
    Anthoney, A.
    Evans, J.
    Haris, N.
    D'Archangelo, M.
    Slater, S.
    Campbell, S.
    Brindley, C.
    Self, S.
    McKeown, P.
    Lavin, S.
    Hynes, D.
    Flores, M. V.
    Pedret-Dunn, A.
    Laffranchi, B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S58 - S59
  • [27] A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas
    Lin, Chia-Chi
    Arkenau, Hendrik-Tobias
    Lu, Sharon
    Sachdev, Jasgit
    de Castro Carpeno, Javier
    Mita, Monica
    Dziadziuszko, Rafal
    Su, Wu-Chou
    Bobilev, Dmitri
    Hughes, Lorraine
    Chan, Jian
    Zhang, Zhi-Yi
    Weiss, Glen J.
    BRITISH JOURNAL OF CANCER, 2019, 121 (02) : 131 - 138
  • [28] A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies.
    Fathi, Amir Tahmasb
    Donnellan, William Bruce
    Lyons, Roger M.
    Maris, Michael B.
    Kim, Tae Min
    Kim, Won Seog
    Schiller, Gary J.
    Abboud, Camille N.
    Arellano, Martha Lucia
    Cull, Elizabeth H.
    Yee, Karen W. L.
    Townsley, Danielle Michelle
    Wang, Fujun
    Bothos, John G.
    Yao, Nai-Shun
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas
    Chia-Chi Lin
    Hendrik-Tobias Arkenau
    Sharon Lu
    Jasgit Sachdev
    Javier de Castro Carpeño
    Monica Mita
    Rafal Dziadziuszko
    Wu-Chou Su
    Dmitri Bobilev
    Lorraine Hughes
    Jian Chan
    Zhi-Yi Zhang
    Glen J. Weiss
    British Journal of Cancer, 2019, 121 : 131 - 138
  • [30] Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders - An open-label, dose-escalation study
    Findling, Robert L.
    Kauffman, Ralph E.
    Sallee, Floyd R.
    Carson, William H.
    Nyilas, Margaretta
    Mallikaarjun, Suresh
    Shoaf, Susan E.
    Forbes, Robert A.
    Boulton, David W.
    Pikalov, Andrei
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2008, 28 (04) : 441 - 446
12345